DoD Peer Reviewed Orthopaedic, Clinical Trial Award | W81XWH 22 PRORP CTA

Opportunity Information: Apply for W81XWH 22 PRORP CTA

The DoD Peer Reviewed Orthopaedic Research Program (PRORP) Clinical Trial Award is a Department of Defense funding opportunity focused on getting practical orthopaedic solutions into real-world patient care faster, especially for injuries that affect military readiness. The program is driven by the scale of musculoskeletal trauma in the military, where extremity injuries make up a major share of combat wounds, and where non-combat injuries from training, sports, and prior conditions can also seriously limit a Service Member's ability to deploy, train, and return to duty. The core idea is that earlier stabilization, treatment, and rehabilitation improve outcomes and can reduce complications, morbidity, and even limb loss. Because of that, the program strongly values research that can move effective care closer to the point of injury and shorten the time it takes for patients to safely return to work or duty.

This award mechanism is specifically for clinical trials in human subjects, not animal studies or preclinical work. In PRORP terms, a clinical trial means human participants are prospectively assigned to one or more interventions (which could include a placebo or control) in order to measure biomedical or behavioral health outcomes. The award is meant to support rapid implementation of trials that could meaningfully change treatment or management of combat-related orthopaedic injuries, as well as non-battle injuries that still have a major impact on unit readiness and return-to-duty rates. The trials can cover a wide range of maturity, from smaller proof-of-concept efforts like pilot studies, first-in-human work, or phase 0 style trials that test feasibility and inform later designs, all the way up to larger studies aimed at determining efficacy in relevant patient populations. Interventions can include promising products, drugs or biologics, devices, clinical guidance, and emerging approaches or technologies, as long as the work is truly structured as a clinical trial.

A notable structural feature is that all applications under this announcement are eligible for Research Level 1. In addition, there is a Collaborative Care Option (Research Level 2) that applies only to applications submitted under the "Translation of Early Findings - Soft Tissue Trauma" focus area. This option is designed to push real interdisciplinary collaboration rather than parallel workstreams. Projects under this option are expected to integrate surgical and rehabilitation strategies into a cohesive plan, so the surgical approach (such as reconstruction, repair, or the use of biologics, pharmaceuticals, or devices to restore tissue architecture and function) is meaningfully linked with the rehabilitation approach (strategies aimed at restoring function and maximizing independence). Applicants have to specify the rehabilitation strategy and the standard of care, and studies that follow patients across the continuum of care are encouraged. To keep the collaboration substantive, the project team must include at least one investigator with orthopaedic rehabilitation expertise and at least one orthopaedic or trauma care clinician, and letters of collaboration from both are required. The opportunity also clarifies what counts as a clinician: someone credentialed and actively practicing in a relevant care role.

Regulatory readiness is a major expectation, especially for FDA-regulated studies. If a trial uses a drug that is not FDA-approved for the proposed investigational use, an Investigational New Drug (IND) application under 21 CFR 312 may be required, and the applicant is responsible for showing evidence from the IRB of record or FDA if an IND is not required. If an IND is required, it must be submitted to FDA within 6 months of the award date, and it must align with the specific product and indication being tested (not a derivative or alternate version). Similarly, if the investigational product is a device, an Investigational Device Exemption (IDE) under 21 CFR 812 may be required; applicants must justify if an IDE is not required or qualifies for an abbreviated IDE, and any required IDE must be submitted within 6 months of the award date. For studies conducted at international sites using an investigational product, applications to each host country's relevant national regulatory authority must also be submitted within 6 months. The announcement is explicit that the government can withdraw funding if an IND, IDE, or international regulatory submission is necessary but not submitted within that 6-month window.

The mechanism places heavy emphasis on feasibility and execution. Preliminary data relevant to the proposed trial are required, which signals that the program is not meant for purely speculative ideas. Applicants must demonstrate access to an appropriate patient population and explain how enrollment targets will be met, including a plan for inclusion of women and minorities that fits the study objectives. They also need to show that the intervention itself will be available for the full study duration, meaning the drug, device, compound, or other materials cannot be hypothetical or inaccessible. On the operational side, the application must show that the team and environment are equipped to run a clinical trial end-to-end, including trial operations, statistical analysis, FDA process knowledge when applicable, and data management. A study coordinator role is specifically called out as important for shepherding the protocol through IRB and other regulatory approvals, coordinating multi-site activity, and managing accrual. If applicable, the institution also needs to show support and willingness to act as the FDA regulatory sponsor and fulfill sponsor responsibilities described in the FDA regulations.

Data integrity and statistical rigor are treated as required fundamentals rather than nice-to-have features. Applications must include a clearly articulated statistical analysis plan, a power analysis that justifies sample size relative to study objectives, and a data management plan that uses an appropriate database to safeguard data integrity. If the trial is FDA-regulated, the database must be 21 CFR Part 11-compliant and use appropriate data standards, reflecting expectations for auditability and regulatory-grade data handling.

There are also public transparency and registration requirements. Funded trials must register on ClinicalTrials.gov before initiating the study. They must also post a copy of the informed consent form on a publicly available federal website in line with federal human subjects requirements described in 32 CFR 219. These requirements are consistent with broader federal expectations for clinical trial accountability and participant protections.

From a funding and award structure standpoint, the DoD will issue these as assistance agreements, meaning either grants or cooperative agreements depending on the anticipated level of DoD involvement during performance. If there is no substantial involvement expected, a grant is used; if substantial involvement is expected (for example, collaboration, participation, or intervention during the research), a cooperative agreement is used. For FY22, the anticipated total cost cap for the entire period of performance is up to $2.5 million for Research Level 1 and up to $3.0 million for Research Level 2. The program planned roughly $10.0 million to fund about four Research Level 1 awards and about $6.0 million to fund about two Research Level 2 awards, for an expected total of six awards, though final funding depends on federal budget availability and the scientific and programmatic merit of submissions.

The timeline expectations are also clearly spelled out. The clinical trial is expected to start within 12 months of the award date, or within 18 months for FDA-regulated studies, reflecting the program's intent to accelerate real clinical impact rather than support slow-moving planning efforts. The opportunity was released under Funding Opportunity Number W81XWH-22-PRORP-CTA by the Department of Defense, Department of the Army (USAMRAA), with an original application closing date of September 13, 2022, and awards planned no later than September 30, 2023. The FY22 funds anticipated for awards were expected to remain available for use through September 30, 2028, consistent with the limited availability window tied to the fiscal year appropriation.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Peer Reviewed Orthopaedic, Clinical Trial Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 08, 2022.
• Applicants must submit their applications by Sep 13, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 6 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 PRORP CTA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: